Get the Stockscreener App
2.9524
0.06%
0.0024
Puma Biotechnology Inc stock is traded at $2.9524, with a volume of 97,879.
It is up +0.06% in the last 24 hours and up +11.39% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$2.95
Open:
$2.98
24h Volume:
97,879
Relative Volume:
0.32
Market Cap:
$146.65M
Revenue:
$226.63M
Net Income/Loss:
$15.38M
P/E Ratio:
-59.05
EPS:
-0.05
Net Cash Flow:
$35.61M
1W Performance:
+5.80%
1M Performance:
+11.39%
6M Performance:
-39.26%
1Y Performance:
+6.18%
1-Day Range:
$2.91
$3.03
1-Week Range:
$2.765
$3.04
52-Week Range:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com - MarketBeat
Puma Biotechnology (PBYI) Set to Announce Quarterly Earnings on Thursday - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ - The Bakersfield Californian
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
What is Zacks Research's Forecast for PBYI FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for PBYI Q3 Earnings - MarketBeat
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well? - Yahoo Finance
Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid - MSN
FY2025 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Decreased by Zacks Research - MarketBeat
Frazier Life Sciences Management L.P. Purchases 246,264 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Affinity Asset Advisors LLC Makes New $815,000 Investment in Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Fred Alger Management LLC Raises Stake in Hamilton Lane Incorporated (NASDAQ:HLNE) - MarketBeat
Hsbc Holdings PLC Has $4.29 Million Position in Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - MarketBeat
The growth track for Humacyte Inc (HUMA) has changed recently - SETE News
Humacyte: Navigating The FDA Uncertainty And ATEV’s Potential (NASDAQ:HUMA) - Seeking Alpha
Puma VCT 13 Launches £70M Share Offer - TipRanks
HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.38 - MarketBeat
It is Poised to be a Bull Market for Puma Biotechnology Inc (PBYI) - SETE News
American Century Companies Inc. Sells 186,924 Shares of Foot Locker, Inc. (NYSE:FL) - Defense World
Bank of America Raises Trupanion (NASDAQ:TRUP) Price Target to $56.00 - MarketBeat
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Insider Selling: Sebelius Kathleen, Humacyte Inc [HUMA] Director divested 5,182 shares - Knox Daily
A$AP Rocky’s Lineup of Puma Sneakers Is Quickly Growing Bigger - Yahoo! Voices
Achilles gains on plans to explore strategic options - XM
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know - Benzinga
Puma VCT 13 PLC Executes Share Buyback - TipRanks
A$AP Rocky’s Distressed PUMA Inhale Is Dropping In “Pop Red” - Sneaker News
A$AP Rocky's PUMA Inhale Distressed Appears in Black and Red - HYPEBEAST
A$ap Rocky x Puma Inhale Distressed Black / Pop RedSep 2024402453-01 - KicksOnFire.com
Puma Biotech's patent suit sees mixed verdict By Investing.com - Investing.com Australia
Upward Trajectory: Humacyte Inc (HUMA) Posts a Slidee, Closing at 5.28 - The Dwinnex
Puma Biotechnology rises on appeal of AstraZeneca Tagrisso patent dispute - MSN
Puma Biotech's patent suit sees mixed verdict - Investing.com
Humacyte Inc (HUMA) can make a big difference with a little luck - SETE News
Puma Biotechnology (NASDAQ:PBYI) investors are sitting on a loss of 79% if they invested five years ago - Yahoo Finance
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment? - Simply Wall St
Puma Biotechnology Inc [NASDAQ: PBYI] Sees Decrease in Stock Value - Knox Daily
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - sharewise
Financial Analysis: Puma Biotechnology Inc (PBYI)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Puma Biotechnology Inc (PBYI) stock in the last session? - US Post News
Q1 2026 EPS Estimates for Puma Biotechnology, Inc. Boosted by Analyst (NASDAQ:PBYI) - MarketBeat
Zacks Research Analysts Decrease Earnings Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) - MarketBeat
Market Momentum: Puma Biotechnology Inc (PBYI) Registers a 4.33 Increase, Closing at 2.65 - The Dwinnex
Puma Biotech confirms court ruling on patent invalidity, disagrees with verdict - MSN
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop - Simply Wall St
Puma Biotech patent claims partially invalidated in court - Investing.com
Puma Biotech patent claims partially invalidated in court By Investing.com - Investing.com India
Puma Biotech confirms court ruling on patent dispute with AstraZeneca - Seeking Alpha
Puma Biotech drops after patents ruled invalid in fight with AstraZeneca over Tagrisso - MSN
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):